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Proprotein convertase subtilisin/kexin 9 (PCSK9) plays an important role in lipid metabolism while available literature regarding its
involvement in the pathogenesis of atherosclerosis and in the expression of genes associated with apoptosis and inflammation is
constantly increasing. Patients with chronic kidney disease (CKD) experience disproportionately increased cardiovascular
morbidity and mortality due to dyslipidemia, accelerated atherosclerosis, inflammation, oxidative stress, and other risk factors.
In the present cross-sectional study, we investigated the possible association of serum PCSK9 levels with markers of
inflammation, oxidative stress, and endothelial damage in patients with CKD. Patients and Methods. Ninety-two patients with
CKD stages II-ΙV (eGFR CKD-EPI 47:3 ± 25:7ml/min/1.73m2, mean age 66 years, 51 men) were included in the study. Plasma
PCSK9 levels were correlated with comorbidities (arterial hypertension, diabetes mellitus, and history of cardiovascular disease),
renal function indices (eGFR, proteinuria–UPR/24 h), lipid parameters (LDL-cholesterol, HDL-cholesterol, triglycerides, Lp(a),
APO-A1, and APO-B), and soluble biomarkers of inflammation, oxidative stress, and endothelial damage (hs-CRP, fibrinogen,
8-epiPGF2a, ox-LDL, IL-6, TNF-α, sICAM-1, and sVCAM-1). Results. The mean plasma value of PCSK9 was 278.1 ng/ml.
PCSK9 levels showed direct correlation with serum triglycerides (p = 0:03), Lp(a) (p = 0:01), and sICAM-1 levels (p = 0:03).
There was no significant correlation between PCSK9 levels and indices of the renal function, other lipid profile parameters,
inflammatory markers, or comorbidities. Multiple regression analysis showed a significant effect of Lp(a) on PCSK9 levels, and
for each unit of higher Lp(a), an increase by 3.082 is expected (95% CI: 0.935-5.228, p = 0:006). At the same time, patients
receiving statins are expected to have on average 63.8 ng/ml higher PCSK9 values compared to patients not receiving statins
(95% CI: 14.6-113.5, p = 0:012). Conclusion. Plasma levels of PCSK9 in nondialysis CKD patients are correlated with endothelial
dysfunction and lipid metabolism parameters. Statin intake increases PCSK9 levels significantly in this patient population.
PCSK9 levels are not correlated with the severity of kidney disease. Major prospective studies are necessary to investigate the
role of PCSK9 in the atherosclerotic cardiovascular outcome in CKD.
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1. Introduction
Chronic kidney disease (CKD) has been characterized as an
atherosclerosis multiplier increasing disproportionally the
incidence of fatal and nonfatal cardiovascular events from
the early stages [1]. Almost a quarter of patients with mild
to moderate CKD have been reported to die mainly due to
atherosclerotic cardiovascular disease (ASCVD) before the
initiation of renal replacement therapy while non-ASCVD
becomes dominant at more advanced stages of CKD [2, 3].
Atherosclerosis, beyond being a lipid disorder, is character-
ized by major inflammatory properties and has been impli-
cated in the pathogenesis of arterial plaque formation and
rupture and in clinical outcomes [4, 5]. Chronic inflamma-
tion, oxidative stress, and endothelial dysfunction separately
and through their crosstalk have direct implications in the
pathogenesis of atherosclerosis in CKD patients and have
been established as nontraditional cardiovascular risk factors
in this frail population [6–9].
Dyslipidemia, on the other hand, is one of the traditional
cardiovascular risk factors. Lipid metabolism dysregulations
are well recognized in patients with CKD [10, 11]. The com-
mon pattern of lipid disorders in a CKD patient consists of
increased levels of triglycerides (TG) and lipoprotein (a)
(Lp(a)), reduced levels of high-density lipoprotein choles-
terol (HDL-C), and normal or slightly reduced total choles-
terol (T-Chol) and low-density lipoprotein cholesterol
(LDL-C) [10, 11]. Proprotein convertase subtilisin/kexin type
9 (PCSK9) has been identified as a central regulator of the
LDL-receptor (LDL-R) expression by binding on the hepato-
cyte LDL-R, causing a reduction in the number of LDL-R and
a subsequent enhancement in circulating LDL-C levels [12].
In CKD patients, existing literature is conflicting about pos-
sible association of PCSK9 plasma levels with the renal func-
tion. In the largest published observational study in two
independent cohorts of nondialysis patients, Rogacev et al.
showed no association of PCSK9 with renal function or with
cardiovascular mortality [13]. Monoclonal antibodies against
PCSK9 (PCSK9i) have emerged as safe and efficient hypolip-
idemic agents. In large clinical trials, PCSK9i manage to
reduce LDL-C to target levels and Lp(a) levels by 20-30%
with additional cardiovascular benefit when added to statin
treatment in high-risk populations [14]. Nevertheless, effi-
cacy of the PCSK9i alirocumab in CKD stage 3 patients was
estimated in an analysis that pooled data from eight phase
III ODYSSEY trials showing an efficacy and safety profile
similar to that of patients with preserved eGFR [15].
Beyond the key role of PCSK9 on lipid disorders and
management, emerging evidence points out its determining
implication in the inflammatory arm of atherosclerosis.
Experimental data have shown the upregulatory effect of pro-
inflammatory and oxidative stress factors on the PCSK9
expression and vice versa, accordingly the possible modula-
tory role of PCSK9 on inflammation mediators [16]. Tumor
necrosis factor alpha (TNF-α) resulted in the induction of
PCSK9 mRNA and protein expression in HepG2 cells and
vascular smooth muscle cells (VSMCs) [17], while oxidized
low-density lipoprotein (ox-LDL) upregulated the PCSK9
expression in different cells, such as vascular endothelial cells
(ECs), VSMCs, macrophages, and dendritic cells [18–23].
The administration of lipopolysaccharide in a PCSK9 knock-
out mice (PCSK9-/-) reduced plasma levels of TNF-α and
interleukin 6 and 10 (IL-6, IL-10) [24], whereas knockdown
of PCSK9 inhibited the inflammatory response in macro-
phages promoted by ox-LDL [19]. Moreover, PCSK9 has
been implicated in endothelial dysfunction by upregulating
the expression of intercellular adhesion molecule-1 (ICAM-1)
and vascular cell adhesion molecule-1 (VCAM-1) in endothe-
lial cells [16].
Experimental results are supported only by a limited
number of clinical studies investigating the putative role of
PCSK9 in the inflammatory process. Plasma levels of inflam-
matory cytokines, TNF-α, IL-6, and IL-8 were decreased in
septic patients with a PCSK9 loss of function allele [24] while
patients with bacteremia had increased PCSK9 plasma
levels in a direct association with CRP [25]. Moreover,
CRP as a marker of inflammation and ASCVD has been
positively associated with plasma levels of PCSK9 both in
patients with acute coronary syndromes and stable coro-
nary disease [26]. In the same line, fibrinogen levels have
been associated with PCSK9 levels in patients with stable
coronary disease independently of traditional cardiovascu-
lar risk confounding [27].
Despite the emerging role of PCSK9 in ASCVD [28],
there is lack of robust clinical data investigating the interplay
of PCSK9 with markers of inflammation, oxidative stress,
and endothelial dysfunction in high-risk patients such as
CKD patients. Having this in mind, we designed a cross-sec-
tional, observational study to investigate possible association
of PCSK9 with inflammation markers, including high-
sensitivity C-reactive protein (hs-CRP), IL-6, TNF-α, oxida-
tive stress markers, 8-isoprostanes (8-epiPGF2a), and ox-
LDL, and endothelial dysfunction markers such as (sICAM-
1) and (sVCAM-1) in a nondialysis population of stable
CKD patients. As a secondary outcome, we investigated the
possible association of PCSK9 levels with renal function
markers, lipid metabolism markers, and echocardiographic
indices.
2. Patients and Methods
2.1. Participants. Ninety-two stable, CKD stage II-ΙV adults
from the outpatient clinics of the Nephrology Department
of our Tertiary Hospital were included in this single-center,
cross-sectional, observational study. Twenty healthy volun-
teers attending the Outpatient Obesity and Lipid Clinic of
the University Hospital of Ioannina, Greece, were recruited
for the study in order to serve as a control group. The exclu-
sion criteria were a recent major cardiovascular event (within
the past 3 months before recruitment), active infection or
history of infection in the last month, severe heart failure
(NYHA IV) and/or severe valvulopathy, hepatic cirrhosis,
active malignancy, and current immunosuppression treat-
ment. All participants after being informed in detail provided
signed informed consent to participate in the study. The
study was approved by the Scientific Committee of the Uni-
versity Hospital of Ioannina, Greece, while all requirements
of Helsinki Declaration were met.
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2.2. Anthropometric Variables—Biochemical Parameters. On
recruitment, all patients underwent a detailed review of their
medical history and a careful clinical examination. The pro-
tocol of the study included recording demographic charac-
teristics, smoking habits and alcohol consumption, primary
renal disease, history of comorbidity and medication, anthro-
pometric measurements, and measurement of blood pressure
and heart rate. A routine full hematologic and biochemical
screening was performed. All laboratory measurements were
carried out after an overnight fast while water consumption
was allowed. Plasma (using EDTA as an anticoagulant) and
serum were prepared from blood samples and stored in ali-
quots at -80°C. Lipid profile assessment included serum levels
of T-Chol, TC, and HDL-C that were determined enzymati-
cally on an Olympus AU600 clinical chemistry analyzer
(Olympus Diagnostica, Hamburg, Germany), LDL-C was
calculated using the Friedewald formula, and Lp(a), apolipo-
protein A1 (APO-A1), and apolipoprotein B (APO-B) were
measured with a Behring Holding GmbH analyzer (Lieder-
bach, Germany). All the above measurements were con-
ducted in the laboratory facilities of the University Hospital
of Ioannina. For the calculation of the estimated glomerular
filtration rate (eGFR, ml/min/1.73m2), the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation
was used [29]. Proteinuria was estimated in a 24-hour urine
collection (UPR, mg/24 h).
2.3. Determination of PCSK9. Plasma PCSK9 concentration
was determined by a quantitative sandwich enzyme immu-
nosorbent assay using a commercially available kit according
to the instructions provided by the manufacturer (R&D Sys-
tems, Inc.) as we previously described [30]. The intra-assay
coefficient of variation ranges from 4.1 to 6.5, and the inter-
assay coefficient of variation ranges from 4.1 to 6.0.
2.4. Determination of 8-epiPGF2a. Serum levels of 8-
epiPGF2a were determined by means of a competitive ELISA
using a commercially available kit (Cayman Chemicals, Ann
Arbor, MI USA), as we previously described [31, 32]. This
method has a specificity of 100% for 8-epiPGF2a, while hav-
ing minimal crossreactivity with other compounds, mostly 8-
isoPGF3a.
2.5. Determination of ox-LDL. Plasma levels of ox-LDL were
measured by a competitive enzyme-linked immunosorbent
assay using a specific murine monoclonal antibody (4E6)
according to the instructions provided by the manufacturer
(Mercodia, Uppsala, Sweden) as we previously described
[32]. Intra- and interassay coefficients of variation were
6.0% and 7.0%, respectively.
2.6. Determination of IL-6 and TNF-α. Serum IL-6 and TNF-
α were measured by a high-sensitivity ELISA (Quantikine HS
human IL-6 and TNF-α, Research & Diagnostic Systems
Europe Ltd., Abington UK). The sensitivity of the ELISA sys-
tem was less than 0.5 pg/ml for both IL-6 and TNF-α.
2.7. Determination of hs-CRP, sICAM-1, and sVCAM-1.
Serum hs-CRP levels were measured by high-sensitivity
immunoturbidimetry (Cobas Integra 800, Roche). Serum
levels of the molecules sICAM-1 and sVCAM-1 were
measured by a sandwich enzyme immunoassay technique
(ELISA) using commercially available standard kits (Quanti-
kine human sICAM-1 and VCAM-1, Research & Diagnostic
Systems Europe Ltd., Abington UK). The sensitivity of the
ELISA system was less than 2ng/ml for both sICAM-1 and
sVCAM-1.
2.8. Echocardiography. Left ventricular mass (LVM) was
assessed by 2D-mode echocardiogram usually within one
week and no longer than one month from study entry, by a
single cardiologist who followed a predefined protocol for
the recordings and measurements and was blinded to the
clinical and biochemical data. LV mass was estimated with
Devereux formula, and LV mass index (LVMI) was calcu-
lated by dividing LV mass with patient’s BMI
[LVMI = LVmass ðgÞ/BSA ðm2Þ] [33, 34]. Left ventricle ejec-
tion fraction (LVEF) and left ventricle shortening fraction
(LVFS) were estimated as well.
3. Statistical Analysis
Frequencies and percentages were used to describe all cate-
gorical data collected, while means with standard deviation
(normally distributed data) and medians with interquartile
range (IQ, nonnormally distributed data) for the scale mea-
surements. Pearson’s correlation coefficient or Spearman’s
rho, depending on the data distribution, was used to assess
linear relationships, while differences in the PCSK9 levels
between dichotomous data were examined with the indepen-
dent samples t-test, after checking the normality assumption
under the Kolmogorov–Smirnov test. Multiple regression
analysis was carried out to test the effect of all independent
parameters for their effect on plasma PCSK9 levels. Included
parameters were all with a p < 0:2 in the univariate analysis
(sex, diabetes mellitus, statin treatment, logUPR, Lp(a), TG,
CRP, fibrinogen, ox-LDL, and sICAM-1). The level of signif-
icance was set at 0.05, and the analysis was conducted using
the SPSS v23.0 software.
4. Results
Patients’ mean age was 66 years, and 51 (55.4%) were males.
Demographic, clinical, and laboratory data and comorbidi-
ties of the 92 patients are shown in Table 1. The mean eGFR
was 47:3 ± 25:7mg/ml/1.73m2, and the median proteinuria
was 323mg/24 h (IQR, 140-1148mg/24 h).
The mean PCSK9 plasma level in CKD patients was
278.10 ng/ml in comparison with significantly lower PCSK9
level in 20 control subjects (mean value 156 ± 43 ng/ml)
(Table 2). Median hs-CRP was 1.0 (0.3-4.3) mg/l, mean
fibrinogen was 433mg/dl, median IL-6 was 3.1 (1.9-4.5)
pg/ml, median TNF-α was 1.9 (1.4-3.0) pg/ml, mean 8-
epiPGF2a was 110 pg/ml, ox-LDL was 79.1U/l, median
sICAM-1 was 240 (200-317) ng/ml, and mean VCAM-1
was 917.3 ng/ml.
4.1. Associations of Kidney Function Parameters. Age, systolic
BP, UPR, uric acid, PTH, and LVMI increased with decreas-
ing eGFR (p < 0:05 for age and p < 0:001 for all other
3Oxidative Medicine and Cellular Longevity
parameters), whereas BMI and hemoglobin decreased with
advanced CKD (p < 0:001 for both). Among lipid profile
markers, only APO-A1 was significantly associated with
eGFR in a direct fashion (p = 0:001). Kidney function
expressed as eGFR showed significant inverse association
with fibrinogen (p < 0:001), IL-6 (p < 0:05), TNF-α
(p < 0:001), 8-epiPGF2a (p < 0:001), and sVCAM-1
(p < 0:001).
Urine protein daily excretion was strongly associated (in
a direct fashion) with TG (p < 0:001), LVMI (p < 0:001), 8-
epiPGF2a (p = 0:007), and sVCAM-1 (p < 0:001).
We did not find a significant association between PCSK9
levels and markers of the kidney function in the nondialysis
CKD population of our study.
4.2. Associations between Inflammation, Oxidative Stress, and
Endothelial Dysfunction Markers. Associations between
inflammation, oxidative stress, and endothelial dysfunction
markers are shown in Table 3. High-sensitivity CRP was
found to have a direct association with fibrinogen
(p < 0:001), IL-6 (p < 0:001), 8-epiPGF2a (p < 0:001), and
sICAM-1 (p < 0:001). Interleukin-6 significantly associated
in a direct manner with fibrinogen (p < 0:001), TNF-α
(p = 0:001), and sVCAM-1 (p < 0:001), while TNF-α and
sVCAM-1 had a direct strong association (p < 0:001).
sVCAM-1 was found to correlate directly with sICAM-1 as
well (p < 0:001). Significant associations of oxidative stress
markers were direct association of 8-epiPGF2a with hs-
CRP, sICAM-1, and sVCAM-1 (p < 0:001, p = 0:001, and p
= 0:003, respectively), while ox-LDL associated directly with
lipid metabolism parameters, TG, T-Chol, LDL-C, and APO-
B (p < 0:001 for all) and with Lp(a) (p = 0:02).
4.3. Associations of PCSK9 with Lipid Metabolism
Parameters, Inflammation, Oxidative Stress, and Endothelial
Dysfunction Markers. PCSK9 levels were directly associated
with TG (p = 0:03), Lp(a) (p = 0:01), and ICAM-1 (p = 0:03)
(Figure 1). There was a significant positive correlation
between PCSK9 levels and statin treatment. Patients on statin
treatment had higher PCSK9 levels in comparison with those
who did not (318.19 ng/ml vs. 253.57 ng/ml, p < 0:001). In
our studied CKD population of stages II-IV, PCSK9 plasma
levels were not associated with kidney function parameters,
diabetes mellitus, and cardiovascular comorbidity or with
echocardiography indices.
Multiple regression analysis, as described above, was con-
ducted to test all independent parameters for their effect on
plasma PCSK9 levels. The results showed a statistically sig-
nificant effect of the Lp(a) values, as well as of statin intake.
Specifically, for each unit of higher Lp(a), an increase by
3.082 is expected for the PCSK9 values (95% CI: 0.935-
5.228, p = 0:006). At the same time, patients receiving statins
are expected to have on average 63.8 ng/ml higher PCSK9
values compared to patients not receiving statins (95% CI:
14.6-113.5, p = 0:012).
5. Discussion
This study shows that in nondialysis CKD patients, plasma
levels of PCSK9 are directly associated with the endothelial
dysfunction biomarker sICAM-1 and with Lp(a), an estab-
lished risk factor for myocardial infraction and cardiovascu-
lar death in CKD patients [35]. A plethora of experimental
Table 1: Demographic characteristics, clinical and laboratory data,






Age (years) 65:8 ± 12:45 35 ± 6
Gender (male), n % 51 (55.4%) 6 (30%)
BMI (kg/m2) 47:29 ± 25:68 22:7 ± 2:0
SBP (mmHg) 142 ± 19 111 ± 12
DPB (mmHg) 81 ± 11 67 ± 8
Hypertension, n % 80 (74%) 0
Diabetes mellitus, n % 26 (28.3%) 0
History of CAD, n % 25 (27%) 0
Statin treatment, n % 33 (36%) 0
eGFR/CKD-EPI (ml/min/1.73
m2)
47:3 ± 25:7 89:5 ± 18:3
UPR (mg/24 h) 323 (140, 1148) —
T-Chol (mg/dl) 209 ± 47 172 ± 27
TG (mg/dl) 163 ± 88 67 ± 32
HDL (mg/dl) 52 ± 15 57 ± 11
LDL (mg/dl) 124 ± 39 102 ± 21
Lp(a) (mg/dl) 11.1 (8.0, 29.3) 8 (1-24)
APO-A1 (mg/dl) 139 ± 30 159 ± 23
APO-B (mg/dl) 93 ± 28 65 ± 15
Albumin (mg/dl) 4:23 ± 0:40 4:4 ± 0:30
Uric acid (mg/dl) 6:82 ± 1:64 5:1 ± 1:35
PTH pg/ml 74 (47, 121) —
Hb (g/dl) 13:0 ± 1:6 13:6 ± 1:4
HbA1c (%) 6.1 (5.7, 7.2) —
LVMI (g/m2) 135:7 ± 47:1 —
EF (%) 69 ± 10 —
FS (%) 37 ± 8 —
Table 2: Levels of PCSK9, inflammation, oxidative stress, and
endothelial dysfunction markers in the 92 CKD patients and the
20 controls.
PCSK9 (ng/ml) 278:10 ± 80:2 156:2 ± 43:1
CRP (mg/l) 1.0 (0.3, 4.3) 1.0 (1.0, 2.2)
Fibrinogen (mg/dl) 433 ± 174 312 ± 136
IL-6 (pg/ml) 3.1 (1.9, 4.5) 0.8 (0.5, 2.6)
TNF-α (pg/ml) 1.9 (1.4, 3.0) 0.7 (0.1, 3.3)
8-epiPGF2a (pg/ml) 110 (92, 138) 45 ± 19
ox-LDL (U/l) 79:1 ± 23:9 42 ± 15
sICAM-1 (ng/ml) 240 (200, 317) 224 ± 20
sVCAM-1 (ng/ml) 917:3 ± 377:1 602:9 ± 145
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and clinical studies have established the central role of
PCSK9 in lipid metabolism while robust evidence supports
the implication of PCSK9 in the inflammatory nature of ath-
erosclerosis [16].
Inflammation, oxidative stress, and endothelial dysfunc-
tion hold a key role in ASCVD in CKD patients. Studies
investigating the role of PCSK9 in atherosclerosis beyond
LDL-C regulation completely lack in the CKD high-risk pop-
ulation. In this clinical study, for the first time, we tested the
possible association of PCSK9 levels with inflammation, oxi-
dative stress, and endothelial dysfunction biomarkers in a
cohort of CKD nondialysis patients. We found that
sICAM-1 levels were directly associated with PCSK9 levels.
The increased levels of sICAM-1 are shown to be an indepen-
dent predictor of mortality in predialysis patients with car-
diovascular disease [36, 37]. In the basic step of
atherosclerotic vascular damage, LDL-C stimulates endothe-
lial cells in the inner layer which express on their surface
ICAM-1 and VCAM-1 and further promote the adhesion
of circulating inflammatory leucocytes. Serum PCSK9 levels
have been evaluated in healthy participants and showed an
independent association with arterial stiffness, a well-
established risk factor for atherosclerotic cardiovascular dis-
ease [38]. Moreover, in patients undergoing coronary angi-
ography for acute coronary syndrome or stable angina,
PCSK9 was found to linearly associate with the fraction and
amount of necrotic core tissue in coronary atherosclerosis,
independently of serum LDL cholesterol levels and statin
use [39]. In an animal model, administration of lipopolysac-
charides in PCSK9 knockout mice diminished the expression
of VCAM-1 from endothelial vascular cells compared with
wild type [16]. Release of ICAM-1 from vascular endothelial
cells was reduced with PCSK9i alirocumab and anti-PCSK9
vaccine AT04 in the APOE∗3Leiden.CETP transgenic mouse
model for hyperlipidemia and atherosclerosis [40, 41].
Among studies estimating PCSK9 levels in nondialysis
CKD patients, only two reported the association of a marker
of inflammation hs-CRP with PCSK9 levels in this popula-
tion. In the first one, with 44 CKD patients (eGFR 20.2
ml/min/1.73m2), the authors reported a rather weak direct
Table 3: Associations between inflammation, oxidative stress,
endothelial dysfunction, and lipid metabolism markers in the
CKD patients.
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Figure 1: Significant associations of PCSK9 with triglycerides,
Lp(a), and sICAM-1 in CKD patients.
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correlation between the two markers (r = 0:26, p < 0:05) [42].
In the largest one, Rogacev et al. assessed PCSK9 levels in two
cohorts of CKD patients (CARE FOR HOMe cohort and
LURIC cohort) and found no correlation between PCSK9
and hs-CRP levels nor with eGFR [13]. In accordance with
Rogacev et al., we did not find any correlation between
plasma PCSK9 levels and neither hs-CRP nor with kidney
function markers, eGFR and UPR, in our patients. Most of
the available studies showed no correlation between PCSK9
and eGFR. Interestingly, one small crossover study has
shown that plasma PCSK9 can be manipulated in response
to therapeutic interventions, which have other hemodynamic
benefits such as endothelin antagonism [43]. Moreover, a
recent experimental study in a LDL-R+/- mouse model
investigated the potential effect of a vaccine targeting PCSK9
(PCSK9Qβ-003) on hypercholesterolemia and kidney fibro-
sis. According to their results, vaccination with PCSK9Qβ-
003 had a positive effect on lipid accumulation and renal
fibrosis through regulation of fatty acid β-oxidation [44].
PCSK9 is suggested to be involved in the dyslipidemia and
proteinuria of nephrotic syndrome in CKD [45, 46]. The
results of a very recent study of Molina-Jijon et al. showed
that the kidney PCSK9 expression was enhanced in the col-
lecting duct of nephrotic patients and animals, supporting
the hypothesis that the kidney could be a major source for
plasma PCSK9 in nephrotic syndrome. In our study, the vast
majority of our patients were not nephrotic [47].
We found that among lipid metabolism parameters,
plasma PCSK9 in our CKD patients correlated directly with
TG and Lp(a) concentrations. Associations of PCSK9 with
lipid profile markers are not consistent in published studies
in the different high cardiovascular risk populations [11–
13]. Dyslipidemia in CKD is characterized mainly by high
TG levels and Lp(a), reduced levels of HDL-C, and normal
or slightly reduced T-Chol and LDL-C [10, 11]. Pathogeneti-
cally, PCSK9 enhances the degradation of hepatic LDL-R,
resulting in an increase in LDL cholesterol levels. We have
found no association between plasma PCSK9 levels and T-
Chol, HDL-C, or LDL-C in our patients. Rogacev et al. did
not find either, while we both found a direct correlation with
TG levels [13]. The absence of an association between PCSK9
and LDL-R might suggest that only a segment of circulating
PCSK9 can mediate the degradation of LDL-R in addition
to the fact that 36% of our patients were receiving statins.
In our study, patients receiving statin had on average 63.8
ng/ml higher PCSK9 values compared to patients not receiv-
ing statins. It is known that statins inhibit 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMGCoAR), a rate-
limiting enzyme in cholesterol biosynthesis, and have been
shown to significantly increase PCSK9mRNA in HepG2 cells
and primary human hepatocytes through activation of the
sterol regulatory element-binding protein-2 (SREBP-2) path-
way [48]. Increased levels of PCSK9 levels in patients on
statin treatment could indicate a possible implication of
PCSK9 in the lipoprotein TG contents by lipoprotein lipase
regulation in CKD patients and an effect on high cardiovas-
cular burden in this patient population. Nevertheless, more
dedicated studies are required in order to elucidate the role
of PCSK9 along with the role of PCSK9i in CKD.
Lipoprotein (a), a subtype of LDL-C, is an established risk
factor for ASCVD in the general and CKD population [11,
49]. The metabolic pathways of Lp(a) production and clear-
ance are not completely elucidated yet. Nevertheless, robust
clinical evidence showed that PCSK9i reduced levels of
Lp(a) by 20-30% and contributed to reduction of incident
major cardiovascular event. Proposed mechanisms are either
by increasing catabolism or by reducing production [49, 50].
In accordance to our results, a direct association between
PCSK9 levels and Lp(a) was found by Bermudez-Lopez
et al. in a cross-sectional study including 209 nondiabetic
CKD patients not receiving statin treatment [51].
In this study, in line with our previous publications, we
found significant associations between severity of CKD and
inflammation (IL-6, TNF-α), oxidative stress (8-epiPGF2),
and endothelial dysfunction (fibrinogen, sICAM-1, and
sVCAM-1) markers and interesting correlations among
these novel biomarkers as part of their well-recognized inter-
play in the uremic milieu [52, 53]. The results of this study
did not demonstrate any association between PCSK9 with
the majority of these biomarkers. On the other hand, a grow-
ing body of experimental evidence, as aforementioned, high-
lights the key role of PCSK9 in the pathogenesis of
atherosclerosis by its implication in inflammation, apoptosis,
oxidative stress, and endothelial damage [16, 54]. Clinical
observational data are conflicting regarding the role of
PCSK9 as a predictive risk factor for mortality in CKD
patients. In a recent prospective study, Strålberg et al.
included 265 patients starting dialysis and found a U shape
association of PCSK9 levels with all-cause mortality indepen-
dently of a number of confounders [55]. In contrast to this
study, Rogacev et al. failed to demonstrate PCSK9 as a prog-
nostic risk factor for cardiovascular outcomes in nondialysis
CKD patients [13].
Our study has some strengths and limitations. To our
knowledge, this is the only clinical observational study exam-
ining the possible association between PCSK9 with a panel of
inflammation, oxidative stress, and endothelial dysfunction
markers in nondialysis CKD patients. The main limitations
of our study are rather small sample size and cross-
sectional observational study design. Again, due to the obser-
vational nature of our findings, causality cannot be inferred
from our data.
6. Conclusion
The emerging experimental data indicate that PCSK9 might
have additional roles other than regulating blood LDL-C,
while PCSK9i have emerged as a very promising category of
hypolipidemic agents for the treatment of high-risk popula-
tions unable to achieve LDL-C target levels. Clinical data in
CKD patients are scarce and not consistent regarding the role
of PCSK9 in the inflammatory arm of atherosclerosis and on
cardiovascular outcome. In our study, we showed that
PCSK9 is possible to be a piece of the complex, unravel puz-
zle of ASCVD in CKD. As CKD patients remain a population
with unmet needs in the management of dyslipidemia and
cardiovascular morbidity and mortality, PCSK9 might be
an interesting therapeutic target for the treatment of
6 Oxidative Medicine and Cellular Longevity
atherosclerotic disease beyond LDL-C regulation. Further
prospective research is warranted to elucidate the effects of
PCSK9 and PCSK9i in patients with reduced renal function.
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